Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Trial to test Cangene's antibody to certain red blood cells in hepatitis C patients begins
May 18th, 2006
Cangene reported the beginning of a clinical trial at Weill Medical College of Cornell University in New York City that will test Cangene's WinRho SDF in patients infected with hepatitis C virus (HCV). Patients infected with HCV currently receive combination treatment with the drugs peginterferon alfa-2 and ribavirin, which can cause severe hematologic effects, including a drop in platelet numbers called thrombocytopenia. Thrombocytopenia leaves the patient's blood unable to clot, possibly causing uncontrolled bleeding that can be fatal. While effective treatments are available for the other blood-related side effects of HCV therapy, thrombocytopenia has remained...
Source: Biotech Business Week (2006-05-18)
|
